171 related articles for article (PubMed ID: 36621840)
1. Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression.
Zhang X; Wang C; Huang C; Yang J; Wang J
Histol Histopathol; 2023 Oct; 38(10):1193-1204. PubMed ID: 36621840
[TBL] [Abstract][Full Text] [Related]
2. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
Li D; Wang X; Yang M; Kan Q; Duan Z
Exp Cell Res; 2019 Jul; 380(1):20-28. PubMed ID: 30904483
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-561-3p indirectly regulates the PD-L1 expression by targeting ZEB1, HIF1A, and MYC genes in breast cancer.
Yousefi A; Sotoodehnejadnematalahi F; Nafissi N; Zeinali S; Azizi M
Sci Rep; 2024 Mar; 14(1):5845. PubMed ID: 38462658
[TBL] [Abstract][Full Text] [Related]
4. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
[TBL] [Abstract][Full Text] [Related]
5. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
6. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
Ashizawa M; Okayama H; Ishigame T; Thar Min AK; Saito K; Ujiie D; Murakami Y; Kikuchi T; Nakayama Y; Noda M; Tada T; Endo H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2019 Jun; 17(6):1403-1413. PubMed ID: 30872332
[TBL] [Abstract][Full Text] [Related]
7. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
8. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
9. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
Wang B; Xu L; Zhang J; Cheng X; Xu Q; Wang J; Mao F
Biomed Pharmacother; 2020 Sep; 129():110268. PubMed ID: 32563146
[TBL] [Abstract][Full Text] [Related]
10. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
11. Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene.
Yahya SMM; Nabih HK; Elsayed GH; Mohamed SIA; Elfiky AM; Salem SM
Breast Cancer Res Treat; 2024 Feb; 204(1):133-149. PubMed ID: 38057687
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
[TBL] [Abstract][Full Text] [Related]
13. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Hu D; Li M; Su J; Miao K; Qiu X
Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260
[TBL] [Abstract][Full Text] [Related]
14. MiRNA-138-5p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis.
Rasoolnezhad M; Safaralizadeh R; Hosseinpourfeizi MA; Banan-Khojasteh SM; Baradaran B
Eur J Pharmacol; 2021 Apr; 896():173933. PubMed ID: 33545160
[TBL] [Abstract][Full Text] [Related]
15. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
16. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.
Kovalchuk O; Filkowski J; Meservy J; Ilnytskyy Y; Tryndyak VP; Chekhun VF; Pogribny IP
Mol Cancer Ther; 2008 Jul; 7(7):2152-9. PubMed ID: 18645025
[TBL] [Abstract][Full Text] [Related]
17. Yin Yang 1-stimulated long noncoding RNA bladder cancer-associated transcript 1 upregulation facilitates esophageal carcinoma progression via the microRNA-5590-3p/programmed cell death-ligand 1 pathway.
Cheng J; Yang Q; Han X; Wang H; Wu K; Zhao H
Bioengineered; 2022 Apr; 13(4):10244-10257. PubMed ID: 35435118
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor effect of miRNA 200-c-3p on A549 non-small cell lung cancer cell line is associated with down-regulation of programmed cell death ligand 1; an immune-check point mechanism.
Ezzat S; Magda I Mohamad ; Manal Basyouni Ahmed ; Sara Elsayed Abdelrahman ; Nesma Hussein Abdel Hay ; Nashwa El-Khazragy ; Maha Imam Ismail
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):13-21. PubMed ID: 38650161
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
